Provided by Tiger Fintech (Singapore) Pte. Ltd.

Regenxbio

7.83
-0.0800-1.01%
Post-market: 7.830.00000.00%19:57 EDT
Volume:404.17K
Turnover:3.17M
Market Cap:392.17M
PE:-1.71
High:7.96
Open:7.90
Low:7.68
Close:7.91
Loading ...

Company Profile

Company Name:
Regenxbio
Exchange:
NASDAQ
Establishment Date:
2008
Employees:
353
Office Location:
9804 Medical Center Drive,Rockville,Maryland,United States
Zip Code:
20850
Fax:
- -
Introduction:
REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy. It also develops RGX-121 for the treatment of mucopolysaccharidosis type II that is in Phase III clinical trial; RGX-111 for treating mucopolysaccharidosis type I; RGX-181 for the treatment of late infantile neuronal ceroid lipofuscinosis type II; and RGX-381 to treat the ocular manifestations of CLN2 disease. In addition, the company licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies. Further, it has a collaboration and license agreement with AbbVie Global Enterprises Ltd. to develop ABBV-RGX-314 outside the United States. REGENXBIO Inc. was incorporated in 2008 and is headquartered in Rockville, Maryland.

Directors

Name
Position
Donald J. Hayden, Jr.
Chairman of the Board, Director
Kenneth T. Mills
President, Chief Executive Officer and Director
A. N. Jerry Karabelas
Director
Alexandra Glucksmann
Director
Allan M. Fox
Director
Daniel J. Abdun Nabi
Director
Daniel Tasse
Director
David C. Stump
Director
Luke M. Beshar
Director

Shareholders

Name
Position
Kenneth T. Mills
President, Chief Executive Officer and Director
Curran Simpson
Senior Vice President, Chief Operations and Technology Officer
Olivier Danos
Senior Vice President, Chief Scientific Officer
Patrick J. Christmas
Senior Vice President, Chief Legal Officer
Steve Pakola
Senior Vice President, Chief Medical Officer
Vittal Vasista
Senior Vice President, Chief Financial Officer